Orvinol-based opioid receptor antagonist fluorinated at C(20)-pharmacophore

Thevinols and their 3-O-demethylated relatives, orvinols, are derivatives of the Diels-Alder adduct of natural alkaloid thebaine with methyl vinyl ketone. Taken together, thevinols and orvinols constitute an important family of opioid receptor (OR) ligands playing an important role in both the OR me...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2024-12, Vol.284, p.117189, Article 117189
Hauptverfasser: Ambartsumyan, A.A., Belozertseva, I.V., Dravolina, O.А., Zvartau, E.E., Sandulenko, I.V., Zelentsova, M.V., Peregudov, A.S., Moiseev, S.K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 117189
container_title European journal of medicinal chemistry
container_volume 284
creator Ambartsumyan, A.A.
Belozertseva, I.V.
Dravolina, O.А.
Zvartau, E.E.
Sandulenko, I.V.
Zelentsova, M.V.
Peregudov, A.S.
Moiseev, S.K.
description Thevinols and their 3-O-demethylated relatives, orvinols, are derivatives of the Diels-Alder adduct of natural alkaloid thebaine with methyl vinyl ketone. Taken together, thevinols and orvinols constitute an important family of opioid receptor (OR) ligands playing an important role in both the OR mediated antinociception and OR antagonism. Herein, we disclose for the first time the antagonist activity of the N-allyl substituted orvinol derivative fluorinated within the pharmacophore associated with C(20) and its surrounding. This compound was prepared via a novel synthetic sequence from 18,19-dihydrothevinone bearing an allyl substituent at N(17) and three fluorine atoms at C(21). Preliminary trials reported earlier demonstrated that the compound exhibited no analgesic activity. However, in vivo experiments conducted in an acute pain model (tail-flick test in mice) demonstrated that this fluorinated compound, when administered at doses of 5–10 mg/kg (sc) 30 min before morphine, exhibited antagonistic activity at the level of naloxone (1 mg/kg, sc) for a longer duration (at least 120 min) compared to naloxone (60 min). Together with the analgesic activity that has been reported for the C(21)-trifluorinated relatives bearing methyl or cyclopropylmethyl substituent at N(17), this result highlights C(21)-fluorinated thevinols and orvinols as the family of opioid receptor ligands (structurally related to buprenorphine, diprenorphine, etc.) covering the full range of activity profiles from agonists to antagonists, which is promising for tuning of their pharmacological properties via a substitution of hydrogen atoms within the pharmacophore associated with C(20) and its surrounding for fluorine. [Display omitted] •The first C(21)-fluorinated orvinol based opioid receptor antagonist.•Opioid antagonist activity comparable to naloxone.•N-Allyl substituent in the fluorinated orvinol renders opioid antagonist activity.•21,21,21-Trifluoroorvinol scaffold for opioid receptor antagonists.•Opioid receptor antagonist fluorinated at C(20)-pharmacophore.
doi_str_mv 10.1016/j.ejmech.2024.117189
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3149537862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523424010717</els_id><sourcerecordid>3149537862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1569-4899a8ea69a339f397f7dbbb1a8b4753ee22e57e21caf202e1270146a1ca6ff63</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhoMozjj6BiJdjovWXNq02QgyeMOB2eg6pOmpk9I2NekM-PZm6OjS1eHA95_Lh9A1wQnBhN81CTQd6G1CMU0TQnJSiBM0JzkvYkaz9BTNMaUszihLZ-jC-wZjnHGMz9GMiZwSWog5etu4veltG5fKQxXZwVhTRQ40DKN1kepH9Wl748eobnfWmV6NAVNjtFpSfBsPW-U6pe2wtQ4u0VmtWg9Xx7pAH0-P76uXeL15fl09rGNNMi7itBBCFaC4UIyJOtxS51VZlkQVZZpnDIBSyHKgRKs6PAeE5pikXIWe1zVnC7Sc5g7Ofu3Aj7IzXkPbqh7szktGUpGxvOA0oOmEame9d1DLwZlOuW9JsDxolI2cNMqDRjlpDLGb44Zd2UH1F_r1FoD7CYDw596Ak14b6DVUJrgbZWXN_xt-AM6jhL4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149537862</pqid></control><display><type>article</type><title>Orvinol-based opioid receptor antagonist fluorinated at C(20)-pharmacophore</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ambartsumyan, A.A. ; Belozertseva, I.V. ; Dravolina, O.А. ; Zvartau, E.E. ; Sandulenko, I.V. ; Zelentsova, M.V. ; Peregudov, A.S. ; Moiseev, S.K.</creator><creatorcontrib>Ambartsumyan, A.A. ; Belozertseva, I.V. ; Dravolina, O.А. ; Zvartau, E.E. ; Sandulenko, I.V. ; Zelentsova, M.V. ; Peregudov, A.S. ; Moiseev, S.K.</creatorcontrib><description>Thevinols and their 3-O-demethylated relatives, orvinols, are derivatives of the Diels-Alder adduct of natural alkaloid thebaine with methyl vinyl ketone. Taken together, thevinols and orvinols constitute an important family of opioid receptor (OR) ligands playing an important role in both the OR mediated antinociception and OR antagonism. Herein, we disclose for the first time the antagonist activity of the N-allyl substituted orvinol derivative fluorinated within the pharmacophore associated with C(20) and its surrounding. This compound was prepared via a novel synthetic sequence from 18,19-dihydrothevinone bearing an allyl substituent at N(17) and three fluorine atoms at C(21). Preliminary trials reported earlier demonstrated that the compound exhibited no analgesic activity. However, in vivo experiments conducted in an acute pain model (tail-flick test in mice) demonstrated that this fluorinated compound, when administered at doses of 5–10 mg/kg (sc) 30 min before morphine, exhibited antagonistic activity at the level of naloxone (1 mg/kg, sc) for a longer duration (at least 120 min) compared to naloxone (60 min). Together with the analgesic activity that has been reported for the C(21)-trifluorinated relatives bearing methyl or cyclopropylmethyl substituent at N(17), this result highlights C(21)-fluorinated thevinols and orvinols as the family of opioid receptor ligands (structurally related to buprenorphine, diprenorphine, etc.) covering the full range of activity profiles from agonists to antagonists, which is promising for tuning of their pharmacological properties via a substitution of hydrogen atoms within the pharmacophore associated with C(20) and its surrounding for fluorine. [Display omitted] •The first C(21)-fluorinated orvinol based opioid receptor antagonist.•Opioid antagonist activity comparable to naloxone.•N-Allyl substituent in the fluorinated orvinol renders opioid antagonist activity.•21,21,21-Trifluoroorvinol scaffold for opioid receptor antagonists.•Opioid receptor antagonist fluorinated at C(20)-pharmacophore.</description><identifier>ISSN: 0223-5234</identifier><identifier>ISSN: 1768-3254</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2024.117189</identifier><identifier>PMID: 39721289</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Fluorinated opioid ligands ; Morphine ; Naloxone ; Opioid receptor antagonists ; Orvinols ; Pharmacophore</subject><ispartof>European journal of medicinal chemistry, 2024-12, Vol.284, p.117189, Article 117189</ispartof><rights>2024 Elsevier Masson SAS</rights><rights>Copyright © 2024 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1569-4899a8ea69a339f397f7dbbb1a8b4753ee22e57e21caf202e1270146a1ca6ff63</cites><orcidid>0000-0002-9104-8725</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmech.2024.117189$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39721289$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ambartsumyan, A.A.</creatorcontrib><creatorcontrib>Belozertseva, I.V.</creatorcontrib><creatorcontrib>Dravolina, O.А.</creatorcontrib><creatorcontrib>Zvartau, E.E.</creatorcontrib><creatorcontrib>Sandulenko, I.V.</creatorcontrib><creatorcontrib>Zelentsova, M.V.</creatorcontrib><creatorcontrib>Peregudov, A.S.</creatorcontrib><creatorcontrib>Moiseev, S.K.</creatorcontrib><title>Orvinol-based opioid receptor antagonist fluorinated at C(20)-pharmacophore</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Thevinols and their 3-O-demethylated relatives, orvinols, are derivatives of the Diels-Alder adduct of natural alkaloid thebaine with methyl vinyl ketone. Taken together, thevinols and orvinols constitute an important family of opioid receptor (OR) ligands playing an important role in both the OR mediated antinociception and OR antagonism. Herein, we disclose for the first time the antagonist activity of the N-allyl substituted orvinol derivative fluorinated within the pharmacophore associated with C(20) and its surrounding. This compound was prepared via a novel synthetic sequence from 18,19-dihydrothevinone bearing an allyl substituent at N(17) and three fluorine atoms at C(21). Preliminary trials reported earlier demonstrated that the compound exhibited no analgesic activity. However, in vivo experiments conducted in an acute pain model (tail-flick test in mice) demonstrated that this fluorinated compound, when administered at doses of 5–10 mg/kg (sc) 30 min before morphine, exhibited antagonistic activity at the level of naloxone (1 mg/kg, sc) for a longer duration (at least 120 min) compared to naloxone (60 min). Together with the analgesic activity that has been reported for the C(21)-trifluorinated relatives bearing methyl or cyclopropylmethyl substituent at N(17), this result highlights C(21)-fluorinated thevinols and orvinols as the family of opioid receptor ligands (structurally related to buprenorphine, diprenorphine, etc.) covering the full range of activity profiles from agonists to antagonists, which is promising for tuning of their pharmacological properties via a substitution of hydrogen atoms within the pharmacophore associated with C(20) and its surrounding for fluorine. [Display omitted] •The first C(21)-fluorinated orvinol based opioid receptor antagonist.•Opioid antagonist activity comparable to naloxone.•N-Allyl substituent in the fluorinated orvinol renders opioid antagonist activity.•21,21,21-Trifluoroorvinol scaffold for opioid receptor antagonists.•Opioid receptor antagonist fluorinated at C(20)-pharmacophore.</description><subject>Fluorinated opioid ligands</subject><subject>Morphine</subject><subject>Naloxone</subject><subject>Opioid receptor antagonists</subject><subject>Orvinols</subject><subject>Pharmacophore</subject><issn>0223-5234</issn><issn>1768-3254</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKxDAUhoMozjj6BiJdjovWXNq02QgyeMOB2eg6pOmpk9I2NekM-PZm6OjS1eHA95_Lh9A1wQnBhN81CTQd6G1CMU0TQnJSiBM0JzkvYkaz9BTNMaUszihLZ-jC-wZjnHGMz9GMiZwSWog5etu4veltG5fKQxXZwVhTRQ40DKN1kepH9Wl748eobnfWmV6NAVNjtFpSfBsPW-U6pe2wtQ4u0VmtWg9Xx7pAH0-P76uXeL15fl09rGNNMi7itBBCFaC4UIyJOtxS51VZlkQVZZpnDIBSyHKgRKs6PAeE5pikXIWe1zVnC7Sc5g7Ofu3Aj7IzXkPbqh7szktGUpGxvOA0oOmEame9d1DLwZlOuW9JsDxolI2cNMqDRjlpDLGb44Zd2UH1F_r1FoD7CYDw596Ak14b6DVUJrgbZWXN_xt-AM6jhL4</recordid><startdate>20241218</startdate><enddate>20241218</enddate><creator>Ambartsumyan, A.A.</creator><creator>Belozertseva, I.V.</creator><creator>Dravolina, O.А.</creator><creator>Zvartau, E.E.</creator><creator>Sandulenko, I.V.</creator><creator>Zelentsova, M.V.</creator><creator>Peregudov, A.S.</creator><creator>Moiseev, S.K.</creator><general>Elsevier Masson SAS</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9104-8725</orcidid></search><sort><creationdate>20241218</creationdate><title>Orvinol-based opioid receptor antagonist fluorinated at C(20)-pharmacophore</title><author>Ambartsumyan, A.A. ; Belozertseva, I.V. ; Dravolina, O.А. ; Zvartau, E.E. ; Sandulenko, I.V. ; Zelentsova, M.V. ; Peregudov, A.S. ; Moiseev, S.K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1569-4899a8ea69a339f397f7dbbb1a8b4753ee22e57e21caf202e1270146a1ca6ff63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Fluorinated opioid ligands</topic><topic>Morphine</topic><topic>Naloxone</topic><topic>Opioid receptor antagonists</topic><topic>Orvinols</topic><topic>Pharmacophore</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ambartsumyan, A.A.</creatorcontrib><creatorcontrib>Belozertseva, I.V.</creatorcontrib><creatorcontrib>Dravolina, O.А.</creatorcontrib><creatorcontrib>Zvartau, E.E.</creatorcontrib><creatorcontrib>Sandulenko, I.V.</creatorcontrib><creatorcontrib>Zelentsova, M.V.</creatorcontrib><creatorcontrib>Peregudov, A.S.</creatorcontrib><creatorcontrib>Moiseev, S.K.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ambartsumyan, A.A.</au><au>Belozertseva, I.V.</au><au>Dravolina, O.А.</au><au>Zvartau, E.E.</au><au>Sandulenko, I.V.</au><au>Zelentsova, M.V.</au><au>Peregudov, A.S.</au><au>Moiseev, S.K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Orvinol-based opioid receptor antagonist fluorinated at C(20)-pharmacophore</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2024-12-18</date><risdate>2024</risdate><volume>284</volume><spage>117189</spage><pages>117189-</pages><artnum>117189</artnum><issn>0223-5234</issn><issn>1768-3254</issn><eissn>1768-3254</eissn><abstract>Thevinols and their 3-O-demethylated relatives, orvinols, are derivatives of the Diels-Alder adduct of natural alkaloid thebaine with methyl vinyl ketone. Taken together, thevinols and orvinols constitute an important family of opioid receptor (OR) ligands playing an important role in both the OR mediated antinociception and OR antagonism. Herein, we disclose for the first time the antagonist activity of the N-allyl substituted orvinol derivative fluorinated within the pharmacophore associated with C(20) and its surrounding. This compound was prepared via a novel synthetic sequence from 18,19-dihydrothevinone bearing an allyl substituent at N(17) and three fluorine atoms at C(21). Preliminary trials reported earlier demonstrated that the compound exhibited no analgesic activity. However, in vivo experiments conducted in an acute pain model (tail-flick test in mice) demonstrated that this fluorinated compound, when administered at doses of 5–10 mg/kg (sc) 30 min before morphine, exhibited antagonistic activity at the level of naloxone (1 mg/kg, sc) for a longer duration (at least 120 min) compared to naloxone (60 min). Together with the analgesic activity that has been reported for the C(21)-trifluorinated relatives bearing methyl or cyclopropylmethyl substituent at N(17), this result highlights C(21)-fluorinated thevinols and orvinols as the family of opioid receptor ligands (structurally related to buprenorphine, diprenorphine, etc.) covering the full range of activity profiles from agonists to antagonists, which is promising for tuning of their pharmacological properties via a substitution of hydrogen atoms within the pharmacophore associated with C(20) and its surrounding for fluorine. [Display omitted] •The first C(21)-fluorinated orvinol based opioid receptor antagonist.•Opioid antagonist activity comparable to naloxone.•N-Allyl substituent in the fluorinated orvinol renders opioid antagonist activity.•21,21,21-Trifluoroorvinol scaffold for opioid receptor antagonists.•Opioid receptor antagonist fluorinated at C(20)-pharmacophore.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>39721289</pmid><doi>10.1016/j.ejmech.2024.117189</doi><orcidid>https://orcid.org/0000-0002-9104-8725</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2024-12, Vol.284, p.117189, Article 117189
issn 0223-5234
1768-3254
1768-3254
language eng
recordid cdi_proquest_miscellaneous_3149537862
source ScienceDirect Journals (5 years ago - present)
subjects Fluorinated opioid ligands
Morphine
Naloxone
Opioid receptor antagonists
Orvinols
Pharmacophore
title Orvinol-based opioid receptor antagonist fluorinated at C(20)-pharmacophore
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A57%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Orvinol-based%20opioid%20receptor%20antagonist%20fluorinated%20at%20C(20)-pharmacophore&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Ambartsumyan,%20A.A.&rft.date=2024-12-18&rft.volume=284&rft.spage=117189&rft.pages=117189-&rft.artnum=117189&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2024.117189&rft_dat=%3Cproquest_cross%3E3149537862%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3149537862&rft_id=info:pmid/39721289&rft_els_id=S0223523424010717&rfr_iscdi=true